<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957112</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000649750</org_study_id>
    <secondary_id>UM-ASA</secondary_id>
    <secondary_id>EU-20970</secondary_id>
    <nct_id>NCT00957112</nct_id>
  </id_info>
  <brief_title>Acupuncture or Self-Acupuncture in Managing Cancer-Related Fatigue in Women Who Have Received Chemotherapy for Stage I, Stage II, or Stage IIIA Breast Cancer</brief_title>
  <official_title>The Efficacy of Acupuncture and Self-acupuncture in Managing Cancer-related Fatigue in Breast Cancer Patients: a Pragmatic Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Acupuncture may help relieve fatigue caused by breast cancer. It is not yet known&#xD;
      whether acupuncture is more effective than self-acupuncture in managing fatigue in women with&#xD;
      breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying acupuncture to see how well it works&#xD;
      compared with self-acupuncture in managing cancer-related fatigue in women who have received&#xD;
      chemotherapy for stage I, stage II, or stage IIIA breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the efficacy of a course of acupuncture in the management of cancer-related&#xD;
           fatigue in a homogeneous sample of women with stage I, II, or IIIA breast cancer who&#xD;
           have completed adjuvant chemotherapy.&#xD;
&#xD;
        -  Assess the efficacy of self-acupuncture in comparison to therapist-administered&#xD;
           acupuncture in sustaining, in the longer term, any effects observed with a 6-week course&#xD;
           of acupuncture in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to study center and&#xD;
      fatigue score (low vs moderate vs severe). Patients are randomized at 3:1 ratio (arm I: arm&#xD;
      II) to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (experimental): Patients undergo a 20-minute acupuncture session once a week for 6&#xD;
           weeks. Patients also receive written information about fatigue and its possible&#xD;
           management.&#xD;
&#xD;
        -  Arm II (control): Patients undergo standard care. They also receive written information&#xD;
           about fatigue as in arm I.&#xD;
&#xD;
      After 6 weeks, patients in arm I are again randomized to 1 of 3 arms.&#xD;
&#xD;
        -  Arm A: Patients receive treatment as in arm I for 4 more weeks.&#xD;
&#xD;
        -  Arm B: Patients receive treatment as in arm II for 4 more weeks.&#xD;
&#xD;
        -  Arm C: Patients learn to self-acupuncture and do so weekly for 4 more weeks. All&#xD;
           patients complete questionnaires on fatigue, hospital anxiety and depression, quality of&#xD;
           life, and use of complementary therapies at baseline and periodically during study.&#xD;
           Patient's sociodemographic and treatment characteristic records are also reviewed.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically for 18 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General fatigue as measured by the Multidimensional Fatigue Inventory</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mental fatigue as measured by the Multidimensional Fatigue Inventory</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety as measured by the Hospital Anxiety and Depression Scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression as measured by the Hospital Anxiety and Depression Scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the FACT-G and Breast Cancer module</measure>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Anxiety Disorder</condition>
  <condition>Breast Cancer</condition>
  <condition>Depression</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo a 20-minute acupuncture session once a week for 6 weeks. Patients also receive written information about fatigue and its possible management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive standard care. They also receive written information about fatigue as in arm I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment as in arm I for 4 more weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive standard care as in arm II for 4 more weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients learn to self-acupuncture and do so weekly for 4 more weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>acupuncture therapy</intervention_name>
    <description>Patients undergo therapist-acupuncture with or without self-acupuncture</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard follow-up care</intervention_name>
    <description>Patients receive standard care</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of breast cancer&#xD;
&#xD;
               -  Stage I, II, or IIIA disease&#xD;
&#xD;
          -  Completed prior chemotherapy for ≥ 1 month and up to 5 years&#xD;
&#xD;
               -  No needling on the ipsilateral arm of patients who have undergone axillary&#xD;
                  dissection&#xD;
&#xD;
               -  No needling on the lymphedematous limbs&#xD;
&#xD;
          -  Score of ≥ 5 on a 0-10 single-item screening fatigue scale, where 0 is no fatigue at&#xD;
             all and 10 is extremely fatigued&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Hematocrit ≥ 30%&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No needle phobia&#xD;
&#xD;
          -  No co-morbidity with any of the following:&#xD;
&#xD;
               -  Bleeding disorder&#xD;
&#xD;
               -  Thyroid dysfunction&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No planned concurrent chemoradiotherapy&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
          -  No concurrent epoetin alfa or transfusion for anemia&#xD;
&#xD;
          -  No other concurrent complementary therapies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Molassiotis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Manchester</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M13 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>anxiety disorder</keyword>
  <keyword>depression</keyword>
  <keyword>fatigue</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

